Trevena (NASDAQ:TRVN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN) in a research note released on Wednesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and issued a $5.00 target price on shares of Trevena in a research note on Thursday, November 14th.

Trevena Stock Up 3.0 %

NASDAQ TRVN opened at $1.74 on Wednesday. The stock has a market cap of $1.50 million, a P/E ratio of -0.04 and a beta of 1.05. Trevena has a twelve month low of $1.13 and a twelve month high of $17.50. The company’s 50-day simple moving average is $1.70 and its 200 day simple moving average is $3.14.

Trevena (NASDAQ:TRVN) last posted its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) EPS for the quarter. The company had revenue of $0.28 million during the quarter. Research analysts anticipate that Trevena will post -23.04 earnings per share for the current year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.